600TiP A first-in-human study of, NUC-7738, a 3'-dA phosphoramidate, in patients with advanced solid tumours (NuTide:701)
Stefan Symeonides(Edinburgh Cancer Research), Sarah P. Blagden(Churchill Hospital), Francesca Aroldi(Churchill Hospital), S. Kestenbaumum(Edinburgh Cancer Research), Neil Harris(Freeman Hospital), Ruth Plummer(National Health Service)
Cited by 1
Related Papers
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
|New England Journal of Medicine|2020|406